NNOX · NANO-X IMAGING LTD Ordinary Shares
View on chartInsiders & Stakes
| Suesskind Dan S Director | ▲ Buy | Open Market | 110,000 Shares held | 9/14/2026 | View profile |
| Meltzer Erez Chief Executive Officer | ▲ Buy | Open Market | 65,443 Shares held | 9/15/2026 | View profile |
| Kainan Noga Director | ▲ Buy | Open Market | 40,792 Shares held | 7/28/2026 | View profile |
| Alroy Erez Director | ▼ Sell | Open Market | 17,075 Shares held | 6/10/2026 | View profile |
| Daniel Ran CFO | ▼ Sell | Other | 5,950 Shares held | 7/29/2026 | View profile |
Transaction History
| Meltzer Erez | ▲ Buy | Open Market | 10,000 | $7K | 9/15/2026 |
| Suesskind Dan S | ▲ Buy | Open Market | 30,000 | $23K | 9/14/2026 |
| Suesskind Dan S | ▲ Buy | Open Market | 30,000 | $23K | 9/14/2026 |
| Meltzer Erez | ▲ Buy | Open Market | 10,000 | $8K | 9/10/2026 |
| Meltzer Erez | ▲ Buy | Open Market | 9,443 | $10K | 8/10/2026 |
| Daniel Ran | ▼ Sell | Other | 1,000 | $890 | 7/29/2026 |
| Kainan Noga | ▲ Buy | Open Market | 33,000 | $30K | 7/28/2026 |
| Suesskind Dan S | ▲ Buy | Open Market | 25,000 | $24K | 7/27/2026 |
| Suesskind Dan S | ▲ Buy | Open Market | 25,000 | $23K | 7/27/2026 |
| Meltzer Erez | ▲ Buy | Open Market | 36,000 | $33K | 7/27/2026 |
| Alroy Erez | ▼ Sell | Open Market | 209 | $345 | 6/10/2026 |
| Alroy Erez | ▼ Sell | Open Market | 469 | $774 | 6/10/2026 |
| Daniel Ran | ▼ Sell | Other | 39,474 | $0 | 3/18/2026 |
| Daniel Ran | ▲ Buy | Open Market | 1,000 | $4K | 9/5/2025 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Nanox Expands 3D Imaging Access
Nano-X Imaging is expanding access to its 3D imaging and diagnostics through an integrated ecosystem. This move aims to broaden the reach of its technology in the medical field. The company remains a high-beta stock, with the current price near its 52-week low of $0.63.
Nanox Expands 3D Imaging Access. Nano-X Imaging is expanding access to its 3D imaging and diagnostics through an integrated ecosystem. This move aims to broaden the reach of its technology in the medical field. The company remains a high-beta stock, with the current price near its 52-week low of $0.63.